Clinical trials: Atopy
Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Moisturization and Skin Hydration Study
Skin moisturization is important for patients with atopic dermatitis, commonly known as eczema. Moisturizing right after bathing is widely accepted as the best method to keep skin hydrated.
- Trial name
- NCT07270965
- Testing
- Moisturizing while in shower/bath, Moisturizing after towel drying
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Dermatitis, Dermatitis, Atopic
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- NCT03627767
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 235 sites in United States, Argentina and 19 more
- Volunteers
- 1,235 people
- Sponsor
- Pfizer
Atopic Dermatitis
Topical Treatment for Atopic Dermatitis
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen.
- Trial name
- NCT06244212
- Testing
- Demonstration of applying triamcinolone cream, Mobile App Use, Standard of Care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Moderate to Severe Atopic Dermatitis
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
This is a prospective, 18-month observational study of adult, adolescent and pediatric Canadian participants with Atopic Dermatitis (AD) commonly known as Eczema, who receive treatment with Dupixent for moderate-to-severe AD…
- Trial name
- CANDID (NCT06099704)
- Where
- 30 sites in Canada
- Volunteers
- 305 people
- Sponsor
- Sanofi
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose…
- Trial name
- NCT06181435
- Testing
- Amlitelimab
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 589 people
- Sponsor
- Sanofi
Atopic Dermatitis
Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis
Novel therapies for AD that avoid immunosuppression and potential carcinogensis are needed. EpiCeram™ , a topical cream, represents a novel class of therapy for skin disorders that does not contain corticosteroids or other…
- Trial name
- NCT00616538
- Testing
- Epiceram(r), Fluticasone Propionate 0.05%
- Volunteers
- 121 people
- Sponsor
- Ceragenix Pharmaceuticals
Dermatitis, Atopic
Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis
The study's objective is to confirm that RHT-3201 reduces the signs and symptoms of moderate atopic dermatitis determined by SCORAD, in patients aged 1 to 12 years, as compared to placebo.
- Trial name
- NCT03907228
- Testing
- RHT-3201
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Moderate-to-Severe Atopic Dermatitis
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03985943
- Testing
- Nemolizumab
- Where
- 174 sites in United States, Australia and 12 more
- Volunteers
- 941 people
- Sponsor
- Galderma R&D
Allergy
Tolerance of Cereals for Atopic Children
In this study, non allergenic cereals will be tested in infants with atopic symptoms. The test will be performed in a hospital.
- Trial name
- NCT01029184
- Testing
- commercialized complete cereals, commercialized complete cereals with additional ingredient
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Société des Produits Nestlé (SPN)
Asthma
Exhaled Nitric Oxide and Nasal Lavage Fluid
The allergic respiratory diseases such as asthma or allergic rhinitis are the main chronic diseases in children. The airway inflammation plays an important role in their pathophysiology.
- Trial name
- NOLN (NCT00773578)
- Testing
- Measurement of exhaled nitric oxide (eNO), Measurement of biomarkers of nasal inflammation
- Where
- France
- Volunteers
- 49 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atopic Dermatitis
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT02176538
- Testing
- Product 0405
- Sponsor
- Fougera Pharmaceuticals Inc.
Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Start Up (NCT06461897)
- Testing
- Upadacitinib, Dupilumab
- Where
- 150 sites in United States, Argentina and 24 more
- Volunteers
- 699 people
- Sponsor
- AbbVie
Atopic Dermatitis (AD)
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD
A multicenter, randomized, double-blind, vehicle-controlled, parallel group trial to demonstrate the superiority of 0.3% and 1% OPA-15406 ointment to vehicle in pediatric subjects with AD.
- Trial name
- NCT05650320
- Testing
- 0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 0% OPA-15406 vehicle
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Otsuka Beijing Research Institute
Atopic Dermatitis
Vitamin D Supplementation in Childhood Atopic Dermatitis
The goal of this clinical trial is to investigate the therapeutic role of vitamin D supplementation in a subset of patients with atopic dermatitis (AD): children with disease onset or worsening in the winter.
- Trial name
- NCT00879424
- Testing
- cholecalciferol (vitamin D)
- Where
- Mongolia
- Volunteers
- 107 people
- Sponsor
- Massachusetts General Hospital
Infant, Very Low Birth Weight, Growth Failure
Preterm Infants on Early Solid Foods
Introduction: Preterm infants with a birth weight less than 1500 grams have special nutritional needs in comparison to full-term neonates.
- Trial name
- PIES-Project (NCT01809548)
- Testing
- Early intervention group, Late intervention group
- Where
- Austria
- Volunteers
- 177 people
- Sponsor
- Medical University of Vienna
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe AD in Part 1 and to describe how…
- Trial name
- ADhope 2 (NCT06526182)
- Testing
- Lebrikizumab
- Where
- 4 sites in Spain
- Volunteers
- 520 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic…
- Trial name
- NCT07765888
- Testing
- Tilrekimig
- Where
- 21 sites in United States, Japan
- Volunteers
- 375 people
- Sponsor
- Pfizer
Atopic Dermatitis
Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis
The purpose of this study is to determine whether oral vitamin D supplementation improves the clinical severity of atopic dermatitis in children.
- Trial name
- VIDATOPIC (NCT01996423)
- Testing
- Vitamin D3
- Where
- Chile
- Volunteers
- 101 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Atopic Dermatitis
Topical L. Reuteri in Children With Atopic Dermatitis
This study evaluates the safety and efficacy of the probiotic L. reuteri vs control product as an adjuvant for improving the skin appearance of children with mild or moderate atopic dermatitis.
- Trial name
- ADreuteri (NCT04265716)
- Testing
- Topical L. reeuteri
- Where
- Mexico
- Volunteers
- 102 people
- Sponsor
- Innovacion y Desarrollo de Estrategias en Salud
Atopic Dermatitis, Eczema
Evaluating the Effect of Bathing Additives in Atopic Dermatitis
This proposed project will be an open-label, split-arm, randomized controlled pilot study. Up to 60 patients diagnosed with atopic dermatitis (eczema) will be enrolled in the study.
- Trial name
- NCT04001855
- Testing
- Dilute vinegar (acetic acid), Dilute bleach
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Arizona